NCT00086385

Brief Summary

The purpose of this study was to examine pharmacological and psychological interventions for smokers over 50.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
403

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Sep 2001

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2001

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

July 1, 2004

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 7, 2004

Completed
4.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2009

Completed
4.6 years until next milestone

Results Posted

Study results publicly available

October 10, 2013

Completed
Last Updated

March 23, 2015

Status Verified

March 1, 2015

Enrollment Period

7.5 years

First QC Date

July 1, 2004

Results QC Date

July 29, 2013

Last Update Submit

March 3, 2015

Conditions

Keywords

Smoking cessationTobacco

Outcome Measures

Primary Outcomes (1)

  • Participants Abstinent From Cigarettes

    Primary outcome variable was 7-day point prevalence cigarette abstinence verified biochemically at week 104

    Two years

Study Arms (4)

Brief Treatment

ACTIVE COMPARATOR

Pharmacological Treatment - Subjects received 12 weeks of bupropion treatment and 10 weeks of nicotine replacement treatment (NRT) Brief Counseling - The counseling intervention consisted of five 90-minute group meetings. There was no further treatment during Weeks 12-52.

Drug: Nicotine polacrilex, Bupropion

Extended NRT

EXPERIMENTAL

Pharmacological Treatment - Following completion of the Brief Treatment, subjects assigned to this condition would continue receiving NRT for up to 52 weeks. Subjects in this condition would be encouraged to continue NRT through Week 24. If a subject terminated NRT and resumed smoking, before Week 50, would be instructed to set a quit date and resume NRT. Counseling Treatment - This is identical to the Brief Counseling described above.

Drug: Nicotine polacrilex, Bupropion

Tailored/No Extended NRT

EXPERIMENTAL

This condition was identical to the Tailored/NRT condition except that no NRT was available after completion of the Brief Treatment.

Drug: Nicotine polacrilex, Bupropion

Extended Tailored Counseling + NRT

EXPERIMENTAL

Tailored Counseling Treatment- The primary goal of the extended treatment was to prevent relapse. Secondary goal was to encourage initiation of abstinence for those who have not attained it by Week 12, and re-initiation of abstinence after slips. Subjects would participate in the Brief Treatment followed by individual sessions. The first extended treatment counseling session would occur at Week 10. Additional sessions would be held every two weeks then every four weeks, and finally at Weeks 44 and 52. Each session would be 20-30 minutes long. Between sessions subjects would be contacted by phone for brief check-ins (5-10 minutes).

Drug: Nicotine polacrilex, Bupropion

Interventions

Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.

Also known as: Nicorette, Zyban
Brief TreatmentExtended NRTExtended Tailored Counseling + NRTTailored/No Extended NRT

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • MULTIPLE

You may not qualify if:

  • MULTIPLE

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

San Francisco

San Francisco, California, 94143, United States

Location

Related Publications (4)

  • Theodoulou A, Fanshawe TR, Leavens E, Theodoulou E, Wu AD, Heath L, Stewart C, Nollen N, Ahluwalia JS, Butler AR, Hajizadeh A, Thomas J, Lindson N, Hartmann-Boyce J. Differences in the effectiveness of individual-level smoking cessation interventions by socioeconomic status. Cochrane Database Syst Rev. 2025 Jan 27;1(1):CD015120. doi: 10.1002/14651858.CD015120.pub2.

  • Theodoulou A, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J, Livingstone-Banks J, Hajizadeh A, Lindson N. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2023 Jun 19;6(6):CD013308. doi: 10.1002/14651858.CD013308.pub2.

  • Barnett PG, Wong W, Jeffers A, Munoz R, Humfleet G, Hall S. Cost-effectiveness of extended cessation treatment for older smokers. Addiction. 2014 Feb;109(2):314-22. doi: 10.1111/add.12404. Epub 2013 Dec 13.

  • Hall SM, Humfleet GL, Munoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. Addiction. 2009 Jun;104(6):1043-52. doi: 10.1111/j.1360-0443.2009.02548.x. Epub 2009 Apr 9.

MeSH Terms

Conditions

Tobacco Use DisorderSmoking Cessation

Interventions

Tobacco Use Cessation DevicesBupropionNicotine Chewing Gum

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental DisordersHealth BehaviorBehavior

Intervention Hierarchy (Ancestors)

TherapeuticsPropiophenonesKetonesOrganic ChemicalsChewing GumPlant GumsBiopolymersPolymersMacromolecular SubstancesPolysaccharidesCarbohydratesCandyFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Limitations and Caveats

The limitations of this study include generalizability, as the population treated was relatively well-educated, willing to participate in research and to attend treatment sessions.

Results Point of Contact

Title
Sharon M. Hall, PhD
Organization
University of California, San Francisco

Study Officials

  • Sharon M Hall, Ph.D.

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 1, 2004

First Posted

July 7, 2004

Study Start

September 1, 2001

Primary Completion

March 1, 2009

Study Completion

March 1, 2009

Last Updated

March 23, 2015

Results First Posted

October 10, 2013

Record last verified: 2015-03

Locations